Market Overview

UPDATE: Goldman Sachs Raises PT to $51, Maintains Sell on Magellan Health Services

Related MGLN
Benzinga's Top Upgrades, Downgrades For May 1, 2018
50 Biggest Movers From Yesterday

Goldman Sachs reiterated its Sell rating on Magellan Health Services (NASDAQ: MGLN) but raised its price target from $46 to $51 on favorable cost trends.

Goldman Sachs commented, "3Q earnings upside was primarily driven by margin expansion as Magellan benefitted from favorable cost trends in the behavioral health segment. Management sees “solid” segment profit growth for next year relative to a 2012 baseline of $240-$245 mn, which excludes prior year developments. [W]e now see somewhat lower procurement risk to the company's Maricopa behavioral health contract, as detail from the recently released RFP (worth $1 bn in annual revenue, including physical health) suggests that Magellan's joint venture with Vanguard Health Systems should not be at any disadvantage in the bidding process."

Magellan Health Services closed at $50.69 on Friday.

Latest Ratings for MGLN

May 2018Raymond JamesUpgradesMarket PerformOutperform
Jul 2017KeyBancUpgradesSector WeightOverweight
Nov 2016BarclaysMaintainsUnderweight

View More Analyst Ratings for MGLN
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (MGLN)

View Comments and Join the Discussion!